Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two…
— Expanded retail access aims to enhance overweight or obesity treatment accessibility CAMPBELL, Calif., May 27, 2025 (GLOBE NEWSWIRE) --…
Presentation at ESMO will follow oral 2025 ASCO Annual Meeting presentation highlighting unprecedented survival data from Phase 2 OVATION 2…
Foro MedCap 2025BIO International Convention 2025 Discovery and Development Europe 2025 MADRID and CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE)…
NEWTOWN, Pa., May 27, 2025 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW) (“Traws Pharma”, “Traws” or “the Company”), a…
$3.25 million upfront with up to an additional $6.5 million of potential aggregate gross proceeds upon the exercise in full of…
Freiburg, Germany--(Newsfile Corp. - May 20, 2025) - Hemostemix Inc. (TSXV: HEM) (OTCQB: HMTXF), a leading Phase III clinical-stage biotechnology…
TOKYO, May 19, 2025 (GLOBE NEWSWIRE) -- MEDIROM Healthcare Technologies Inc. (Nasdaq CM: MRM), a holistic healthcare company based in…
PALO ALTO, Calif., May 16, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating…
30+ studies across diverse conditions illuminate the unique value of functional lung imaging with Xenon MRIDURHAM, NC and LONDON, May…